Sana Biotechnology, Inc.
SANA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -1.34 | 0.08 | -0.23 |
| FCF Yield | -68.18% | -34.47% | -41.79% | -10.90% |
| EV / EBITDA | -1.37 | -3.03 | -2.63 | -7.04 |
| Quality | ||||
| ROIC | -58.26% | -63.60% | -37.03% | -34.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.90 | 1.08 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 6.22% | 12.00% | -10.68% | -73.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.12 | 0.27 | 0.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -122.76 | -48.58 | -37.60 | -45.21 |